This Ameet Mallik thing is an intriguing rumor. So
Post# of 153834
(Total Views: 629)
Posted On: 02/16/2022 6:39:17 PM
Re: Buddyboy20 #118275
This Ameet Mallik thing is an intriguing rumor. Some bits and pieces.....
From the Rafael Holdings website....
" Ameet Mallik to Transition CEO Role to Chairman, Howard Jonas, and Will Remain a Highly Engaged Member of the Company’s Board of Directors and Chair Newly Established Transition Committee -"
"- Patrick Fabbio, Chief Financial Officer, to Assume the Additional Role of President"
Patrick Fabbio was previously employed with Progenics Pharmaceuticals.
Ameet Mallik appears to retweet Novartis posts frequently.
Its website states:
"Rafael Holdings is focused on developing novel cancer and immune therapies. The company owns the Barer Institute, and is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd. Through the Barer Institute, the company is developing a pipeline of compounds focused on the regulation of cancer and immune metabolism."
Cancer and immune metabolism......sounds familiar. Unfortunately, they only seem to have the one drug, Devimistat.
Rafael Pharma missed endpoints on October 28 in two trials with their lead drug, Devimistat: one for Metastatic Pancreatic Cancer, one for Relapsed or Refactory Acute Myeloid Leukemia. It is now enrolling a new trial for Biliary Tract Cancer.
Rafael's stock dropped from $30 to $8 that day. It's currently at $3.60.
From the Rafael Holdings website....
" Ameet Mallik to Transition CEO Role to Chairman, Howard Jonas, and Will Remain a Highly Engaged Member of the Company’s Board of Directors and Chair Newly Established Transition Committee -"
"- Patrick Fabbio, Chief Financial Officer, to Assume the Additional Role of President"
Patrick Fabbio was previously employed with Progenics Pharmaceuticals.
Ameet Mallik appears to retweet Novartis posts frequently.
Its website states:
"Rafael Holdings is focused on developing novel cancer and immune therapies. The company owns the Barer Institute, and is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd. Through the Barer Institute, the company is developing a pipeline of compounds focused on the regulation of cancer and immune metabolism."
Cancer and immune metabolism......sounds familiar. Unfortunately, they only seem to have the one drug, Devimistat.
Rafael Pharma missed endpoints on October 28 in two trials with their lead drug, Devimistat: one for Metastatic Pancreatic Cancer, one for Relapsed or Refactory Acute Myeloid Leukemia. It is now enrolling a new trial for Biliary Tract Cancer.
Rafael's stock dropped from $30 to $8 that day. It's currently at $3.60.
(3)
(0)